Multiple bioinformatics software was used to predict the potential phosphorylation sites of C9orf72 by Cdk5, followed by verification of whether Cdk5‐inhibitor ROSCOVITINE could reverse the degradation of C9orf72 in PD. This evidence concerns the gene CDK5 and Parkinson disease.